Data have demonstrated that women with higher FPG levels at baseline had a greater risk of developing GDM at approximately 26 weeks, which coincides with the period of elevated maternal endogenous glucose production and reduced insulin sensitivity (35, 36). The gene discussed is INS; the disease is gestational diabetes.